The Lung Cancer Program (LCP) is a translational research program with three major goals:
- Define molecular pathways that contribute to the development and progression of lung cancer;
- Identify individuals at high risk for lung cancer and improve early detection of lung cancer; and
- Improve prevention and therapy for lung cancer.
The LCP's research interests and expertise encompass a wide variety of relevant areas, including the study of growth factors and hormones and their receptors in the human airway, polymorphisms in cell cycle and DNA repair enzymes that may alter risk for lung cancer, identification of lung cancer biomarkers using proteomics and genomics, mechanisms of induction of radiation damage in cells and tissues, and lung cancer antigen discovery. The program also emphasizes novel therapeutic trial development, using both new systemic therapies as well as new techniques for radiation delivery.
LCP research projects are highly interdisciplinary in nature and involve investigators with clinical expertise, expertise in population studies, and expertise in the basic sciences. The LCP is also home to the translational UPCI Specialized Program of Research Excellence (SPORE) in Lung Cancer from the National Cancer Institute.